Memory Disorders

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
AriceptPhase 21 trial
Active Trials
UP
UCB PharmaBelgium - Brussels
1 program
PiracetamN/A1 trial
Active Trials
NCT00567060Completed676Est. Jan 2004

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
UCB PharmaPiracetam

Clinical Trials (2)

Total enrollment: 676 patients across 2 trials

Prevention of Cognitive Decline in Alzheimer's Disease by Ingested Interferon Alpha

Phase 2Unknown

Efficacy and Safety of Piracetam Taken for 12 Months in Subjects Suffering From Mild Cognitive Impairment (MCI)

Start: May 2000Est. completion: Jan 2004676 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space